RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Off-the-Shelf CAR t cells show promise against Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of cancer treatment called ALLO-715, which uses donor immune cells engineered to attack myeloma cells. It was given to 73 adults whose multiple myeloma had returned or stopped responding to at least three prior treatments. The goal was to …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:53 UTC
-
New drug safety check for Hard-to-Treat blood cancer
Disease control CompletedThis study looked at the safety of the drug Kyprolis (carfilzomib) in 101 Indian adults whose multiple myeloma had come back or stopped responding to treatment. Researchers tracked side effects and how long patients lived without their cancer getting worse. The goal was to confir…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated May 22, 2026 13:53 UTC